CME

Faculty: Natalie S. Callander, MD

This online educational activity reviews the clinical evidence supporting anti-CD38 monoclonal antibody–based combinations as foundational frontline therapy for patients with newly diagnosed multiple myeloma. Faculty examine pivotal clinical trial data and current NCCN Guidelines across transplant-eligible and transplant-ineligible populations, highlighting the impact of anti-CD38 therapy on depth and durability of response. The program utilizes patient cases to emphasize fitness- and risk-adapted approaches to treatment selection that take patient comorbidities, frailty, cytogenetic risk, and treatment goals into account. Through real-world clinical perspectives, participants will learn strategies to implement guideline-concordant regimens, optimize treatment delivery, and improve outcomes in community practice.

Faculty: Saad Z. Usmani, MD, MBA

Faculty: Natalie S. Callander, MD

This online educational activity reviews the clinical evidence supporting anti-CD38 monoclonal antibody–based combinations as foundational frontline therapy for patients with newly diagnosed multiple myeloma. Faculty examine pivotal clinical trial data and current NCCN Guidelines across transplant-eligible and transplant-ineligible populations, highlighting the impact of anti-CD38 therapy on depth and durability of response. The program utilizes patient cases to emphasize fitness- and risk-adapted approaches to treatment selection that take patient comorbidities, frailty, cytogenetic risk, and treatment goals into account. Through real-world clinical perspectives, participants will learn strategies to implement guideline-concordant regimens, optimize treatment delivery, and improve outcomes in community practice.

Faculty: Saad Z. Usmani, MD, MBA

This online educational activity reviews the clinical evidence supporting anti-CD38 monoclonal antibody–based combinations as foundational frontline therapy for patients with newly diagnosed multiple myeloma. Faculty examine pivotal clinical trial data and current NCCN Guidelines across transplant-eligible and transplant-ineligible populations, highlighting the impact of anti-CD38 therapy on depth and durability of response. The program utilizes patient cases to emphasize fitness- and risk-adapted approaches to treatment selection that take patient comorbidities, frailty, cytogenetic risk, and treatment goals into account. Through real-world clinical perspectives, participants will learn strategies to implement guideline-concordant regimens, optimize treatment delivery, and improve outcomes in community practice.

Faculty: Saad Z. Usmani, MD, MBA

Faculty: Natalie S. Callander, MD

This online educational activity reviews the clinical evidence supporting anti-CD38 monoclonal antibody–based combinations as foundational frontline therapy for patients with newly diagnosed multiple myeloma. Faculty examine pivotal clinical trial data and current NCCN Guidelines across transplant-eligible and transplant-ineligible populations, highlighting the impact of anti-CD38 therapy on depth and durability of response. The program utilizes patient cases to emphasize fitness- and risk-adapted approaches to treatment selection that take patient comorbidities, frailty, cytogenetic risk, and treatment goals into account. Through real-world clinical perspectives, participants will learn strategies to implement guideline-concordant regimens, optimize treatment delivery, and improve outcomes in community practice.

Faculty: Carolyn Lam, MD, PhD

Faculty: Stephen J. Greene, MD

Using a real-world patient case, Dr. Stephen Greene and Dr. Carolyn Lam explore strategies to optimize care for patients with heart failure with reduced ejection fraction (HFrEF) who remain at elevated risk despite guideline-directed medical therapy (GDMT). The discussion examines the importance of avoiding clinical inertia, addressing persistent residual risk, and using biomarkers such as NT-proBNP to guide treatment decisions. Faculty also review the mechanism of action of the soluble guanylate cyclase stimulator vericiguat and evidence from the VICTORIA and VICTOR trials evaluating its use across a spectrum of ambulatory HFrEF populations, as well as findings from the VELOCITY study supporting a 5-mg starting dose and simplified titration to the target dose. Practical guidance is provided on integrating vericiguat with established HFrEF therapies, including patient selection, dosing, and tolerability, with the goal of reducing the risk of cardiovascular death and worsening heart failure in appropriate patients.

Faculty: Federico Alberici, MD, PhD

Faculty: Anastasia Liossatou, PhD, RN

Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.

Topics include validated assessment tools such as WI-NRS and Itch-MOS, integration of patient-reported outcomes (PROMs), and the role of interdisciplinary care involving nephrologists, dermatologists, and nurses. Experts also discuss approaches to improving documentation, symptom tracking, and clinical communication. The series emphasizes the value of holistic care models and the importance of addressing quality of life concerns in CKD management.

Faculty: Steven Fishbane, MD

Faculty: Nancy Helou, PhD

Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.

Topics include validated assessment tools such as WI-NRS and Itch-MOS, integration of patient-reported outcomes (PROMs), and the role of interdisciplinary care involving nephrologists, dermatologists, and nurses. Experts also discuss approaches to improving documentation, symptom tracking, and clinical communication. The series emphasizes the value of holistic care models and the importance of addressing quality of life concerns in CKD management.

Faculty: Steven Fishbane, MD

Faculty: Nancy Helou, PhD

Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.

Topics include validated assessment tools such as WI-NRS and Itch-MOS, integration of patient-reported outcomes (PROMs), and the role of interdisciplinary care involving nephrologists, dermatologists, and nurses. Experts also discuss approaches to improving documentation, symptom tracking, and clinical communication. The series emphasizes the value of holistic care models and the importance of addressing quality of life concerns in CKD management.

Faculty: Steven Fishbane, MD

Faculty: Nancy Helou, PhD

Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.

Topics include validated assessment tools such as WI-NRS and Itch-MOS, integration of patient-reported outcomes (PROMs), and the role of interdisciplinary care involving nephrologists, dermatologists, and nurses. Experts also discuss approaches to improving documentation, symptom tracking, and clinical communication. The series emphasizes the value of holistic care models and the importance of addressing quality of life concerns in CKD management.

Faculty: Nancy Helou, PhD

Faculty: Steven Fishbane, MD

Join faculty experts in reviewing best practices for chronic kidney disease–associated pruritus (CKD-aP), a common but under-recognized symptom affecting patients with CKD. Through expert interviews, case discussions, and brief lectures, the series examines the psychosocial burden of CKD-aP and outlines practical strategies for symptom recognition, assessment, and management.

Topics include validated assessment tools such as WI-NRS and Itch-MOS, integration of patient-reported outcomes (PROMs), and the role of interdisciplinary care involving nephrologists, dermatologists, and nurses. Experts also discuss approaches to improving documentation, symptom tracking, and clinical communication. The series emphasizes the value of holistic care models and the importance of addressing quality of life concerns in CKD management.